CureVac Unveils Strong Q2 & H1 2024 Financials and Key Business Updates

• CureVac closed a new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront, validating its mRNA platform.
• The company initiated a strategic workforce reduction of approximately 30% by the end of 2024 to focus on high-value opportunities in oncology and infectious diseases.
• CureVac invoiced a €10 million milestone payment after transitioning its avian influenza (H5N1) program to Phase 2, fully licensed to GSK.
• The first patient was dosed in a Phase 1 study for glioblastoma with the CVGBM vaccine, with initial data accepted for presentation at ESMO.
• The Supervisory Board was strengthened with the appointment of Birgit Hoffman and Mehdi Shahidi, M.D., while CFO Pierre Kemula will step down on October 31, 2024.
• As of June 30, 2024, CureVac reported cash and cash equivalents of €202.5 million, reaffirming its cash runway into 2028, despite a decrease from €402.5 million at the end of 2023.

The next important date, Quarterly report, at CureVac is on 15.08.2024.

CureVac

+10,55 %

+18,10 %

+1,05 %

-20,94 %

-59,79 %

-94,69 %

-90,50 %

-90,50 %

-93,49 %

ISIN:NL0015436031WKN:A2P71U

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max